Archives
AHA: Muvalaplin Reduces Lipoprotein(a) Levels in Individuals With Cardiovascular Risk
Reduction in levels seen using an intact lipoprotein(a) assay and apolipoprotein(a)-based assay
AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
More than 39 million U.S. adults qualify for indications other than weight management alone
AHA: Initial Catheter Ablation Beneficial for Ventricular Tachycardia
Initial strategy of catheter ablation leads to lower risk for composite primary end point versus antiarrhythmic drug therapy
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo
AHA: Intensive Strategy for Lowering Systolic BP Beneficial in Type 2 Diabetes
Significantly lower incidence of major cardiovascular events seen with intensive- versus standard-treatment strategy
ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related Disease
Flare-free, treatment-free complete remission and flare-free, glucocorticoid-free complete remission improved with inebilizumab
ACR: Colchicine No Benefit for Painful Knee Osteoarthritis
No significant improvements seen in knee pain, function, or size of synovial effusions versus placebo
AHA: Rising Outdoor Temperatures Tied to Higher Risk for Atrial Fibrillation
Doubling to tripling of odds seen when temperatures reach extreme heat levels
AHA: AI Analysis of Images, Videos Can ID Early Hypertension, Diabetes
Authors say technology may enable noninvasive screening
AHA: Rural-Urban Disparities Persist in Cardiovascular Mortality
Worst trend seen among younger rural adults, while improvements seen in older adults in all areas
